Literature DB >> 24871355

Evolving indications for Descemet's stripping automated endothelial keratoplasty.

Peter B Veldman1, Mark A Terry, Michael D Straiko.   

Abstract

PURPOSE OF REVIEW: Recent advances in the field of endothelial transplantation, including increasing acceptance of Descemet's membrane endothelial keratoplasty, may alter the indications for Descemet's stripping automated endothelial keratoplasty, to a procedure reserved for complex endothelial disorders. RECENT
FINDINGS: Recent literature demonstrates that Descemet's membrane endothelial keratoplasty provides better and faster visual outcomes and decreased immunologic rejection compared to Descemet's stripping automated endothelial keratoplasty. However, Descemet's membrane endothelial keratoplasty may be more challenging in the management of a number of more complex endothelial disorders. While the literature on complex Descemet's membrane endothelial keratoplasty is limited, the utility of Descemet's stripping automated endothelial keratoplasty has been validated in the management of endothelial dysfunction in the setting of a number of comorbid conditions including prior penetrating keratoplasty, prior glaucoma surgery, iridocorneal endothelial syndrome, aniridia, aphakia, and anterior chamber intraocular lenses, among others.
SUMMARY: The increasing adoption of Descemet's membrane endothelial keratoplast is changing the practice of endothelial keratoplasty. However, limitations of the Descemet's membrane endothelial keratoplasty procedure have also served to crystallize the essential role of Descemet's stripping automated endothelial keratoplasty in many complex endothelial keratoplasty scenarios. This article will review indications for endothelial keratoplasty, along with the current evidence for Descemet's stripping automated endothelial keratoplasty and Descemet's membrane endothelial keratoplasty in their management.

Entities:  

Mesh:

Year:  2014        PMID: 24871355     DOI: 10.1097/ICU.0000000000000073

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  7 in total

1.  Descemet Stripping Endothelial Keratoplasty for Congenital Aniridia: An Interesting and Challenging Story.

Authors:  Michael Tsatsos; Ioannis Athanasiadis; Nikolaos Ziakas
Journal:  Turk J Ophthalmol       Date:  2022-06-29

2.  Generation and Feasibility Assessment of a New Vehicle for Cell-Based Therapy for Treating Corneal Endothelial Dysfunction.

Authors:  Naoki Okumura; Kazuya Kakutani; Ryota Inoue; Daiki Matsumoto; Tomoki Shimada; Makiko Nakahara; Yumiko Kiyanagi; Takehiro Itoh; Noriko Koizumi
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

3.  Role of therapeutic contact lens following Descemet's stripping automated endothelial keratoplasty: A randomized control trial.

Authors:  Ritika Mukhija; Prafulla K Maharana; Neelima Aron; Rajesh Sinha; Namrata Sharma; Gita Satpathy; Jeewan S Titiyal; Tushar Agarwal
Journal:  Indian J Ophthalmol       Date:  2021-01       Impact factor: 1.848

4.  Eye bank versus surgeon prepared Descemet stripping automated endothelial keratoplasty tissues: Influence on adhesion force in a pilot study.

Authors:  Vito Romano; Mohit Parekh; Ahmed Kazaili; Bernhard Steger; Riaz Akhtar; Stefano Ferrari; Stephen B Kaye; Hannah J Levis
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

Review 5.  Diagnosis and Management of Iridocorneal Endothelial Syndrome.

Authors:  Marta Sacchetti; Flavio Mantelli; Marco Marenco; Ilaria Macchi; Oriella Ambrosio; Paolo Rama
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

6.  Resolution of Corneal Fibrosis After Descemet's Stripping Automated Endothelial Keratoplasty: A Case Report.

Authors:  Marta Zola; Jaeryung Kim; Myrsini Petrelli; Lydia Schmutz; Kattayoon Hashemi; George Kymionis
Journal:  Ophthalmol Ther       Date:  2020-03-06

7.  Revaluating the relationship between keratoplasty and intraocular lenses.

Authors:  Jesse Panthagani; Ankur Barua
Journal:  Eye (Lond)       Date:  2020-04-15       Impact factor: 3.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.